NEW YORK — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The Phase 3 randomized, observer-blinded study (NCT06178991) enrolled more than 8,000 adults 18 through 64 years of age to evaluate the …
COMIRNATY may not protect all people
Main – An updated COVID-19 vaccine is tailored by Pfizer-BionTech to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older. You should NOT get COMIRNATY® (COVID-19 Vaccine, mRNA) if you had a severe allergic reaction to a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine or to any ingredient …
Pfizer-BioNTech Win Prix Galien Canada Innovative Product Award for COMIRNATY
KIRKLAND, QUEBEC and MAINZ, GERMANY – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that COMIRNATY, the Pfizer-BioNTech COVID-19 Vaccine, has been named the 2023 winner of the Prix Galien Canada Innovative Product Award. COMIRNATY is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in …
Health Canada authorizes Pfizer-BioNTech Covid-19 vaccine targeting Omicron XBB.1.5
Ottawa – Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant for individuals six months of age and older. Health Canada received Pfizer-BioNTech’s submission on June 29, 2023. After a thorough and independent review of the evidence, Health Canada has determined that the vaccine meets the Department’s stringent safety, efficacy and quality requirements. …
Health Canada authorizes Moderna Covid-19 vax targeting Omicron XBB.1.5 subvariant
Ottawa – Health Canada has authorized the use of the Moderna SPIKEVAX™ Covid-19 vaccine targeting the Omicron XBB.1.5 subvariant for people six months of age and older. Health Canada received Moderna’s submission for its new Covid-19 vaccine on June 29, 2023. After a thorough, independent review of the evidence, Health Canada has determined that the vaccine meets the Department’s stringent safety, …
AstraZeneca Vaxzevria COVID-19 vaccine
Ottawa – All COVID-19 vaccines authorized in Canada are proven safe, effective and of high quality. Name: AstraZeneca Vaxzevria® COVID-19 vaccine Manufacturer: AstraZeneca Canada Inc and Verity/SII (COVISHIELD) Type: Viral vector-based Status: Approved by Health Canada Approved for: Age 18 and older How it’s given: Injection in muscle (usually the upper arm) Number of doses: 2 doses Note: The COVISHIELD version of this vaccine provided a temporary …
Pfizer-BioNTech on Covid-19 Vaccine Supply Agreement with EU
NEW YORK— Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have reached an agreement with the European Commission (EC) to amend their existing contract to deliver Covid-19 vaccines to the European Union. The amended agreement reflects the companies’ commitment to working collaboratively to help address ongoing public health needs, while respecting the principles of the original …